Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonist
Zealand Pharma A/S and Helsinn Healthcare SA announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.
Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sub-licensees. In return Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones for an undisclosed amount. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma has retains the marketing rights to the Nordic countries. The total value of the non royalty portion of the partnership is valued up to € 140 million.
Zealand's pre-clinical studies have demonstrated that ZP1846 inhibits chemotherapy-induced injury in the small intestine, and as a result also reduces the incidence and severity of chemotherapy-induced diarrhea.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
